These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16889606)

  • 1. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
    Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
    Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
    Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
    Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
    Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R
    Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.
    Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Kayler LK; Erkan E; McFeaters CG; James G; Grosso MJ; Zeevi A; Gray EA; Marcos A; Starzl TE
    Am J Transplant; 2007 Dec; 7(12):2736-8. PubMed ID: 17908272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.
    Tan HP; Kaczorowski DJ; Basu A; Khan A; McCauley J; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplantation; 2004 Dec; 78(11):1683-8. PubMed ID: 15591960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.
    Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z
    Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP; Kaczorowski D; Basu A; McCauley J; Marcos A; Donaldson J; Unruh M; Randhawa P; Zeevi A; Shapiro R
    Transplant Proc; 2005 Dec; 37(10):4235-40. PubMed ID: 16387087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
    Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
    Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
    Thai NL; Khan A; Tom K; Blisard D; Basu A; Tan HP; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplantation; 2006 Dec; 82(12):1621-4. PubMed ID: 17198247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
    Chan K; Taube D; Roufosse C; Cook T; Brookes P; Goodall D; Galliford J; Cairns T; Dorling A; Duncan N; Hakim N; Palmer A; Papalois V; Warrens AN; Willicombe M; McLean AG
    Transplantation; 2011 Oct; 92(7):774-80. PubMed ID: 21836540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
    Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
    Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.